Praxis Precision Medicines, Inc. (PRAX) Stock Forecast
PRAX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.55 / 5 from 20 analysts
- Price target
- $650.00 average of analyst targets
- Upside to target
- +168.9% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-3.66
- 52-week range
- $164.09 – $386.33
PRAX analyst ratings
20 analystsNumber of analysts at each rating.
PRAX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRAX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.63 | −$5.60 | −$2.74 | −$3.36 | −8.2% | 19 |
| Current fiscal year (2026) | −$14.02 | −$19.83 | −$12.07 | −$13.48 | −4.0% | 19 |
| Next fiscal year (2027) | −$9.49 | −$17.88 | $5.36 | −$14.02 | +32.3% | 18 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRAX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 17 |
| Current fiscal year (2026) | $830,710 | $0 | $6.9M | 0.0% | 19 |
| Next fiscal year (2027) | $345.1M | $140.2M | $674.4M | +41,442.6% | 20 |
PRAX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRAX revenue: reported and forecast
PRAX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$4.02 | −$3.63 | −$3.63 | −$3.63 | −$3.63 | −9.7% | 12 up · 4 down |
| Current fiscal year (2026) | −$15.30 | −$13.94 | −$13.94 | −$13.94 | −$14.02 | −8.3% | 15 up · 1 down |
| Next fiscal year (2027) | −$9.66 | −$9.41 | −$9.29 | −$9.33 | −$9.49 | −1.7% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRAX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRAX beat in 7 of 12.
What analysts expect from PRAX
20 analysts cover Praxis Precision Medicines; their consensus rating is strong buy (4.55 on a 1–5 scale, where 5 is a strong buy). The average price target is $650.00, 168.9% above the latest close of $241.76. Analysts expect earnings of −$14.02 per share for 2026, −4.0% from a year earlier. For 2027 the average estimate is −$9.49 per share on revenue of $345.1 million. Praxis Precision Medicines beat the EPS estimate in 7 of the last 12 quarters.
Related: PRAX income statement, PRAX key metrics, PRAX chart. See the PRAX stock overview for the latest quote and news.
PRAX forecast FAQ
What is Praxis Precision Medicines's price target?
The average analyst price target for Praxis Precision Medicines is $650.00, 168.9% above the latest close of $241.76.
Is Praxis Precision Medicines a buy, hold or sell?
Of 20 analysts covering Praxis Precision Medicines, 15 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 1 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Praxis Precision Medicines's EPS forecast?
Analysts forecast −$14.02 per share for 2026 (range −$19.83 to −$12.07); for 2027 the estimate is −$9.49.
What is Praxis Precision Medicines's revenue forecast?
The average revenue estimate for 2026 is $0.8 million, growth of 0.0%; for 2027 it is $345.1 million.
When does Praxis Precision Medicines report earnings?
Praxis Precision Medicines is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-3.66.
Does Praxis Precision Medicines usually beat earnings estimates?
Praxis Precision Medicines reported EPS at or above the analyst estimate in 7 of the last 12 quarters.